UniQure Stock Plummets After FDA Rejects Gene Therapy

Key Developments

UniQure NV (NASDAQ:QURE) shares experienced a sharp decline of 36% following a decision by the U.S. Food and Drug Administration (FDA). The agency informed the company that the existing data from its early- to mid-stage trial for AMT-130, a gene therapy for Huntington’s disease, is insufficient to support a marketing application.

Situational Overview

The FDA concluded that the results from the studies for AMT-130, when compared to an external control group, cannot be used as the primary evidence of effectiveness needed for regulatory approval. This conclusion was detailed in the final minutes of a meeting held on January 30. AMT-130 is a gene therapy delivered directly to the brain, designed to treat the rare, neurodegenerative Huntington’s disease.

Market Impact and Analyst Reactions

The market reaction was immediate and severe, with analysts describing the FDA's decision as a significant setback. Leerink analysts called it the "worst case scenario for many investors." Stifel analysts noted the news was disappointing but not entirely surprising, pointing to the need for a sham-controlled study which introduces new risks. Meanwhile, Truist analysts found the FDA's recommendation inconsistent with guidance provided for other central nervous system gene therapies.

Summary and Next Steps

UniQure now faces uncertainty regarding the path forward for AMT-130. The company plans to engage further with regulators and has scheduled a Type B meeting with the FDA in the second quarter to discuss potential future study designs and clarify the requirements for approval.

FAQ

Q: Why did UniQure's stock price fall sharply?
A: The stock fell 36% after the U.S. FDA announced that the company's clinical trial data for its Huntington's disease gene therapy, AMT-130, would not support a marketing application.

Q: What was the FDA's specific concern?
A: The FDA determined that the study results, compared against an external control, could not serve as the primary evidence of effectiveness required for approval.

Q: What is UniQure's plan now?
A: The company expects to hold a Type B meeting with the FDA in the second quarter of the year to discuss future study designs.

Source: Investing.com